TSE:BLU BELLUS Health - BLU Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding BELLUS Health Inc. Please log in to your account or sign up in order to add this asset to your watchlist. C$10.64 +0.22 (+2.11%) (As of 03/21/2023 12:00 AM ET) Add Compare Share Share Today's RangeC$10.30▼C$10.6750-Day RangeC$9.89▼C$11.1152-Week RangeC$7.41▼C$16.24Volume41,240 shsAverage Volume51,395 shsMarket CapitalizationC$1.34 billionP/E RatioN/ADividend YieldN/APrice TargetC$20.00 ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesHeadlinesSocial Media About BELLUS Health (TSE:BLU) StockBELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.Read More Receive BLU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BELLUS Health and its competitors with MarketBeat's FREE daily newsletter. Email Address BLU Stock News HeadlinesMarch 6, 2023 | msn.com4 Biotech Stocks That Could Break Through the MarketMarch 1, 2023 | finance.yahoo.comBELLUS Health to Participate in the Cowen 43rd Annual Health Care ConferenceMarch 22, 2023 | Upexi, Inc (Ad)The Stock That Is Flying Under Wall St. RadarWith The Founder OF XPO Logistics Leading The Way This Nasdaq Company is Ready and GOING!February 1, 2023 | markets.businessinsider.comTSX Recovers After Mid-session Setback, Ends Just Marginally DownJanuary 20, 2023 | markets.businessinsider.comTSX Rises 0.8%, Ends At 1-month HighDecember 20, 2022 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Innate Pharma SA (OtherIPHYF) and BELLUS Health (BLU)December 16, 2022 | markets.businessinsider.comCanadian Shares Extending Losses As Growth Worries Weight On SentimentNovember 17, 2022 | finance.yahoo.comBELLUS Health Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS LagsMarch 22, 2023 | Upexi, Inc (Ad)The Stock That Is Flying Under Wall St. RadarWith The Founder OF XPO Logistics Leading The Way This Nasdaq Company is Ready and GOING!October 11, 2022 | seekingalpha.comBLU BELLUS Health Inc.September 7, 2022 | theglobeandmail.comClosing Bell: Bellus Health Inc down on Friday (BLU)August 14, 2022 | seekingalpha.comBELLUS Health (BLU) Investor Presentation - SlideshowAugust 10, 2022 | finance.yahoo.comBELLUS Health Reports Second Quarter 2022 Financial Results and Business HighlightsAugust 3, 2022 | finance.yahoo.comDo Institutions Own BELLUS Health Inc. (TSE:BLU) Shares?July 13, 2022 | finance.yahoo.comBELLUS Health Shares Slide On Public Offering Of Shares In Canada And USJuly 12, 2022 | finance.yahoo.comBELLUS Health Announces FDA End-of-Phase 2 Meeting For Refractory Chronic Cough ProgramJuly 12, 2022 | finance.yahoo.comBellus Health Announces Positive End-of-Phase 2 Meeting with the FDA and its CALM Phase 3 Program for BLU-5937 in Refractory Chronic CoughJuly 11, 2022 | finance.yahoo.comHas Bellus Health (BLU) Outpaced Other Medical Stocks This Year?June 7, 2022 | finance.yahoo.comAre Medical Stocks Lagging Bellus Health (BLU) This Year?June 1, 2022 | finance.yahoo.comBELLUS Health to Participate in the Jefferies Healthcare ConferenceMay 30, 2022 | finance.yahoo.comBELLUS Health (TSE:BLU) Is In A Good Position To Deliver On Growth PlansMay 20, 2022 | fool.caIs Bellus Health Stock Still a Buy After 30% Earnings Jump?May 2, 2022 | finance.yahoo.comBELLUS Health to Present Late-Breaking Clinical Data from the Phase 2b SOOTHE Trial of BLU-5937 at the ATS 2022 International ConferenceApril 27, 2022 | benzinga.comBELLUS Health to Participate in Multiple Upcoming...February 23, 2022 | apnews.comBellus: Q4 Earnings SnapshotJanuary 25, 2022 | nasdaq.comBELLUS Health Inc. Common Shares (BLU)December 21, 2021 | finance.yahoo.comIs BELLUS Health (TSE:BLU) In A Good Position To Invest In Growth?See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive BLU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BELLUS Health and its competitors with MarketBeat's FREE daily newsletter. Email Address BLU Company Calendar Today3/21/2023Next Earnings (Estimated)3/22/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolTSE:BLU CUSIPN/A CIKN/A Webwww.bellushealth.com Phone+1-450-6804500FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price ForecastC$20.00 High Stock Price ForecastC$24.00 Low Stock Price ForecastC$16.00 Forecasted Upside/Downside+88.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)C($0.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-72,600,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-28.91% Return on Assets-16.72% Debt Debt-to-Equity Ratio0.15 Current Ratio16.96 Quick Ratio16.40 Sales & Book Value Annual SalesC$16,000.00 Price / Sales83,650.35 Cash FlowC$2.28 per share Price / Cash Flow4.67 Book ValueC$3.23 per share Price / Book3.29Miscellaneous Outstanding Shares125,790,000Free FloatN/AMarket CapC$1.34 billion OptionableNot Optionable Beta-0.51 Key ExecutivesMr. Roberto Francesco Bellini (Age 43)Pres, CEO & Director Comp: $353.03kMr. Ramzi Benamar (Age 50)Chief Financial Officer Comp: $607.33kDr. Denis Garceau (Age 66)Chief Scientific Officer Comp: $431.87kMr. Tony Matzouranis (Age 50)Sr. VP of Bus. Devel. Comp: $272.89kDr. Catherine M. Bonuccelli M.D. (Age 65)Chief Medical Officer Comp: $703.77kDr. Andreas Orfanos FFPM (Age 64)M.B.B.Ch, MBA, Chief Operating Officer Mr. Daniel MatthewsDirector of Investor Relations & CommunicationsMr. Sebastien Roy (Age 47)Corp. Sec. More ExecutivesKey CompetitorsConcordia InternationalTSE:CXRCronos GroupTSE:CRONTrillium TherapeuticsTSE:TRILCanopy GrowthTSE:WEEDdentalcorpTSE:DNTLView All CompetitorsInsidersPierre LarochelleSold 35,667 sharesTotal: C$448,976.20 ($12.59/share)Joseph RusSold 35,643 sharesTotal: C$432,559.88 ($12.14/share)Francois DesjardinsSold 14,053 sharesTotal: C$118,989.56 ($8.47/share)View All Insider Transactions BLU Stock - Frequently Asked Questions Should I buy or sell BELLUS Health stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BELLUS Health in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BLU shares. View BLU analyst ratings or view top-rated stocks. What is BELLUS Health's stock price forecast for 2023? 2 equities research analysts have issued 12-month price objectives for BELLUS Health's stock. Their BLU share price forecasts range from C$16.00 to C$24.00. On average, they expect the company's stock price to reach C$20.00 in the next year. This suggests a possible upside of 88.0% from the stock's current price. View analysts price targets for BLU or view top-rated stocks among Wall Street analysts. How have BLU shares performed in 2023? BELLUS Health's stock was trading at C$11.08 at the beginning of 2023. Since then, BLU stock has decreased by 4.0% and is now trading at C$10.64. View the best growth stocks for 2023 here. When is BELLUS Health's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 22nd 2023. View our BLU earnings forecast. What other stocks do shareholders of BELLUS Health own? Based on aggregate information from My MarketBeat watchlists, some companies that other BELLUS Health investors own include Exxon Mobil (XOM), Bombardier (BDRBF), AbbVie (ABBV), Energy Transfer (ET), General Electric (GE), Coca-Cola (KO), Alexion Pharmaceuticals (ALXN), Advanced Micro Devices (AMD), Boeing (BA) and Walt Disney (DIS). What is BELLUS Health's stock symbol? BELLUS Health trades on the Toronto Stock Exchange (TSX) under the ticker symbol "BLU." How do I buy shares of BELLUS Health? Shares of BLU stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. What is BELLUS Health's stock price today? One share of BLU stock can currently be purchased for approximately C$10.64. How much money does BELLUS Health make? BELLUS Health (TSE:BLU) has a market capitalization of C$1.34 billion and generates C$16,000.00 in revenue each year. The company earns C$-72,600,000.00 in net income (profit) each year or C($0.96) on an earnings per share basis. How can I contact BELLUS Health? BELLUS Health's mailing address is 9-275 Armand-Frappier Blvd, LAVAL, QC H7V 4A7, Canada. The official website for the company is www.bellushealth.com. The company can be reached via phone at +1-450-6804500. This page (TSE:BLU) was last updated on 3/22/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.